Dagmara Klasa-Mazurkiewicz

Prof. Dagmara Klasa-Mazurkiewicz

Dept of Gynecology and Perinatology, Gdańsk Medical University, Gdańsk, Pomorskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Clinical Biochemistry
Verified
Journal Article
Closed access
JNJoanna Narkiewicz
Joanna Narkiewicz
DKDagmara Klasa-Mazurkiewicz
Dagmara Klasa-Mazurkiewicz
DZDorota Zurawa-Janicka
Dorota Zurawa-Janicka
JSJoanna Skorko-Glonek
Joanna Skorko-Glonek
JEJanusz Emerich
Janusz Emerich
BLBarbara Lipinska
Barbara Lipinska

1 December 2009 in Contraception
Verified
Journal Article
Closed access
ATAlexander Teichmann
Alexander Teichmann
DADan Apter
Dan Apter
JEJanusz Emerich
Janusz Emerich
KGKlaus Greven
Klaus Greven
DKDagmara Klasa-Mazurkiewicz
Dagmara Klasa-Mazurkiewicz
DSDaniele Spielmann
Daniele Spielmann

24 October 2020 in Genes
Verified
Journal Article
Open access
PDF file
Marcin ŚniadeckiMarcin Śniadecki
Marcin Śniadecki
MBMichał Brzeziński
Michał Brzeziński
KDKatarzyna Darecka
Katarzyna Darecka
DKDagmara Klasa-Mazurkiewicz
Dagmara Klasa-Mazurkiewicz
Patryk PoniewierzaPatryk Poniewierza
Patryk Poniewierza
DWDariusz Wydra
Dariusz Wydra
Current oncological developments are based on improved understanding of genetics, and especially the discovery of genes whose alterations affect cell functions with consequences for the whole body. Our work is focused on the one of these genes, BRCA1-associated RING domain protein 1 (BARD1), and its oncogenic role in breast cancer. Most importantly, the study points to new avenues in the treatment and prevention of the most frequent female cancer based on BARD1 research. The BARD1 and BRCA1 (BReast CAncer type 1) proteins have similar structures and functions, and they combine to form the new molecule BARD1-BRCA1 heterodimer. The BARD1-BRCA1 complex is involved in genetic stabilization at the cellular level. It allows to mark abnormal DNA fragments by attaching ubiquitin to them. In addition, it blocks (by ubiquitination of RNA polymerase II) the transcription of damaged DNA. Ubiquitination, as well as stabilizing chromatin, or regulating the number of centrosomes, confirms the protective cooperation of BARD1 and BRCA1 in the stabilization of the genome. The overexpression of the oncogenic isoforms BARD1β and BARD1δ permit cancer development. The introduction of routine tests, for instance, to identify the presence of the BARD1β isoform, would make it possible to detect patients at high risk of developing cancer. On the other hand, introducing BARD1δ isoform blocking therapy, which would reduce estrogen sensitivity, may be a new line of cancer therapy with potential to modulate responses to existing treatments. It is possible that the BARD 1 gene offers new hope for improving breast cancer therapy.

1 April 2009 in Gynecologic Oncology
Verified
Journal Article
Closed access
DKDagmara Klasa-Mazurkiewicz
Dagmara Klasa-Mazurkiewicz
JNJoanna Narkiewicz
Joanna Narkiewicz
TMTomasz Milczek
Tomasz Milczek
BLBarbara Lipińska
Barbara Lipińska
JEJanusz Emerich
Janusz Emerich

1 January 2011
Verified
Journal Article
Closed access
DKDagmara Klasa-Mazurkiewicz
Dagmara Klasa-Mazurkiewicz
MJMirosław Jarząb
Mirosław Jarząb
TMTomasz Milczek
Tomasz Milczek
BLBarbara Lipińska
Barbara Lipińska
JEJanusz Emerich
Janusz Emerich

11 July 2011 in Folia Histochemica et Cytobiologica
Verified
Journal Article
Open access
PDF file
PLPiotr Laudanski
Piotr Laudanski
OKOksana Kowalczuk
Oksana Kowalczuk
DKDagmara Klasa-Mazurkiewicz
Dagmara Klasa-Mazurkiewicz
TMTomasz Milczek
Tomasz Milczek
DRDominik Rysak-Luberowicz
Dominik Rysak-Luberowicz
LCLech Chyczewski
Lech Chyczewski
The aim of this study was to selectively profile the activation status of mammalian target of rapamycin (mTOR)-associated oncogenes and tumor suppressor genes (TSGs) in ovarian cancer specimens, healthy ovaries and benign ovarian tumors, including endometrial cysts. We used a novel type of microfluidic gene array to examine the expression of 15 human tumor suppressors and oncogenes in ovarian cancer specimens of 53 patients, benign ovarian cysts of 29 women (endometrial and simple) and 11 healthy ovaries of individuals in whom the material was obtained during total hysterectomies performed because of fibroid changes. The array was custom-designed to include the following genes: NF1, RHEB, mTOR1, AKT-1, PTEN, TSC1, TSC2, KRAS, RPS6KB1, 4EBP1, TP53, EIF4E, STK11, PIK3CA and BECN1. Confirmatory immunohistochemical detection was performed for a group of selected proteins. Particularly significant differences were observed as to the expression of PTEN (p < 0.0001), TP53 (p = 0.0003), PIK3CA (p = 0.0003) and BECN1 (p = 0.0014) which were shown to be downregulated in cancer patients when compared to healthy ovaries and benign ovarian cysts (endometrial and simple). These markers did not show association with grade or stage of the tumor. Immunohistochemistry showed that PTEN, TP53, PIK3CA and BECN1 proteins are expressed in ovarian cancer. Our results indicate that there are significant differences in the expression of some of the mTOR-related tumor suppressors and oncogenes which could be associated with the pathogenesis of ovarian cancer. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 317–324) The aim of this study was to selectively profile the activation status of mammalian target of rapamycin (mTOR)-associated oncogenes and tumor suppressor genes (TSGs) in ovarian cancer specimens, healthy ovaries and benign ovarian tumors, including endometrial cysts. We used a novel type of microfluidic gene array to examine the expression of 15 human tumor suppressors and oncogenes in ovarian cancer specimens of 53 patients, benign ovarian cysts of 29 women (endometrial and simple) and 11 healthy ovaries of individuals in whom the material was obtained during total hysterectomies performed because of fibroid changes. The array was custom-designed to include the following genes: NF1, RHEB, mTOR1, AKT-1, PTEN, TSC1, TSC2, KRAS, RPS6KB1, 4EBP1, TP53, EIF4E, STK11, PIK3CA and BECN1. Confirmatory immunohistochemical detection was performed for a group of selected proteins. Particularly significant differences were observed as to the expression of PTEN (p < 0.0001), TP53 (p = 0.0003), PIK3CA (p = 0.0003) and BECN1 (p = 0.0014) which were shown to be downregulated in cancer patients when compared to healthy ovaries and benign ovarian cysts (endometrial and simple). These markers did not show association with grade or stage of the tumor. Immunohistochemistry showed that PTEN, TP53, PIK3CA and BECN1 proteins are expressed in ovarian cancer. Our results indicate that there are significant differences in the expression of some of the mTOR-related tumor suppressors and oncogenes which could be associated with the pathogenesis of ovarian cancer. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 317–324)